Statement Of Cash Flows [Abstract]

Pharming Group N.V. - Filing #2154299

Concept 2023-01-01 to
2023-12-31
2022-01-01 to
2022-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Adjustments for finance income
3,663,000 USD
4,485,000 USD
Cash flows from (used in) operations before changes in working capital
2,569,000 USD
23,995,000 USD
Increase (decrease) in working capital
16,961,000 USD
387,000 USD
Adjustments for decrease (increase) in trade and other receivables
18,539,000 USD
2,364,000 USD
Adjustments for increase (decrease) in trade and other payables
16,228,000 USD
11,992,000 USD
Adjustments for depreciation and amortisation expense and impairment loss (reversal of impairment loss) recognised in profit or loss
15,925,000 USD
13,188,000 USD
Adjustments for gain (loss) on disposal of investments in subsidiaries, joint ventures and associates
USD
12,242,000 USD
Cash flows from (used in) investing activities [abstract]
Cash flows from (used in) decrease (increase) in restricted cash and cash equivalents
216,000 USD
273,000 USD
Proceeds from sales of interests in associates
USD
7,300,000 USD
Purchase of financial instruments, classified as investing activities
382,014,000 USD
USD
Proceeds from sales or maturity of financial instruments, classified as investing activities
232,811,000 USD
USD

Talk to a Data Expert

Have a question? We'll get back to you promptly.